Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

References

• BlockGAHulbert-ShearonTELevinNWPortFKAssociation of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national studyAm J Kidney Dis19983146076179531176
   PubMed Web of Science ®Google Scholar
• GaneshSKStackAGLevinNWHulbert-ShearonTPortFKAssociation of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patientsJ Am Soc Nephrol200112102131213811562412
   PubMed Web of Science ®Google Scholar
• GoodmanWGGoldinJKuizonBDYoonCGalesBSiderDCoronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysisN Engl J Med2000342201478148310816185
   PubMed Web of Science ®Google Scholar
• ChertowGMBurkeSKRaggiPSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int200262124525212081584
   PubMed Web of Science ®Google Scholar
• ChertowGMRaggiPMcCarthyJTSchulmanGSilberzweigJKuhlikAThe effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patientsAm J Nephrol200323530731412915774
   PubMed Web of Science ®Google Scholar
• FerramoscaEBurkeSChasan-TaberSRattiCChertowGMRaggiPPotential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patientsAm Heart J2005149582082515894962
   PubMed Web of Science ®Google Scholar
• BlockGASpiegelDMEhrlichJMehtaRLindberghJDreisbachAEffects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysisKidney Int20056841815182416164659
   PubMed Web of Science ®Google Scholar
• GoodmanWGHladikGATurnerSABlaisdellPWGoodkinDALiuWThe Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidismJ Am Soc Nephrol20021341017102411912261
   PubMed Web of Science ®Google Scholar
• QuarlesLDSherrardDJAdlerSRosanskySJMcCaryLCLiuWThe calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal diseaseJ Am Soc Nephrol200314357558312595492
   PubMed Web of Science ®Google Scholar
• LindbergJSMoeSMGoodmanWGCoburnJWSpragueSMLiuWThe calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidismKidney Int200363124825412472790
   PubMed Web of Science ®Google Scholar
• LindbergJSCulletonBWongGBorahMFClarkRVShapiroWBCinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter studyJ Am Soc Nephrol200516380080715689407
   PubMed Web of Science ®Google Scholar
• BlockGAMartinKJde FranciscoALTurnerSAAvramMMSuranyiMGCinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisN Engl J Med2004350151516152515071126
   PubMed Web of Science ®Google Scholar
• StrippoliGFPalmerSTongAElderGMessaPCraigJCMeta-analysis of biochemical and patient-level effects of calcimimetic therapyAm J Kidney Dis200647571572616632010
   PubMed Web of Science ®Google Scholar
• MartinKJJuppnerHSherrardDJGoodmanWGKaplanMRNassarGFirst- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HClKidney Int20056831236124316105056
   PubMed Web of Science ®Google Scholar
• FukagawaMYumitaSAkizawaTUchidaETsukamotoYIwasakiMCinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patientsNephrol Dial Transplant200823132833517717030
   PubMed Web of Science ®Google Scholar
• MessaPMacarioFYaqoobMBoumanKBraunJvon AlbertiniBThe OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismClin J Am Soc Nephrol200831364518178780
   PubMed Web of Science ®Google Scholar
• MoeSMCunninghamJBommerJAdlerSRosanskySJUrena-TorresPLong-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HClNephrol Dial Transplant200520102186219316030053
   PubMed Web of Science ®Google Scholar
• SterrettJRStromJStummvollHKBahnerUDisneyASorokaSDCinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidismClin Nephrol2007681101717703830
   PubMed Web of Science ®Google Scholar
• ChertowGMBlumenthalSTurnerSRoppoloMSternLChiEMCinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium × phosphateClin J Am Soc Nephrol20061230531217699221
   PubMed Web of Science ®Google Scholar
• BlockGAZeigSSugiharaJChertowGMChiEMTurnerSACombined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidismNephrol Dial Transplant2008In press
   Web of Science ®Google Scholar
• ArenasMDAlvarez-UdeFGilMTMoledousAMalekTNunezCImplementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysisNephrol Dial Transplant20072261639164417277339
   PubMed Web of Science ®Google Scholar
• LazarEHebertKPomaTStankusNLong-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidismAm J Nephrol200727327427817429197
   PubMed Web of Science ®Google Scholar
• SpiegelDMCaseyLBellSParkerMChoncholMAchieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practiceHemodial Int200610Suppl 2S242717022747
   PubMedGoogle Scholar
• BrownEMMacLeodRJExtracellular calcium sensing and extracellular calcium signalingPhysiol Rev2001811239297
   Web of Science ®Google Scholar
• BrownEMClinical lessons from the calcium-sensing receptorNat Clin Pract Endocrinol Metab20073212213317237839
   PubMedGoogle Scholar
• SilverJLeviRRegulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney diseaseKidney Int Suppl200595S81215882315
   PubMed Web of Science ®Google Scholar
• PollakMRBrownEMChouYHHebertSCMarxSJSteinmannBMutations in the human Ca(2+)−sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidismCell1993757129713037916660
   PubMed Web of Science ®Google Scholar
• HoCConnerDAPollakMRLaddDJKiforOWarrenHBA mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidismNat Genet19951143893947493018
   PubMed Web of Science ®Google Scholar
• GogusevJDuchambonPHoryBGiovanniniMGoureauYSarfatiEDepressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidismKidney Int19975113283368995751
   PubMed Web of Science ®Google Scholar
• KiforOMooreFDJrWangPGoldsteinMVassilevPKiforIReduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidismJ Clin Endocrinol Metab1996814159816068636374
   PubMed Web of Science ®Google Scholar
• BrownAJRitterCSFinchJLSlatopolskyEADecreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphateKidney Int19995541284129210200992
   PubMed Web of Science ®Google Scholar
• RitterCSFinchJLSlatopolskyEABrownAJParathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptorKidney Int20016051737174411703591
   PubMed Web of Science ®Google Scholar
• DruekeTMartinDRodriguezMCan calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studiesNephrol Dial Transplant20072271828183917449493
   PubMed Web of Science ®Google Scholar
• CollotonMShatzenEMillerGStehman-BreenCWadaMLaceyDCinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney Int200567246747615673294
   PubMed Web of Science ®Google Scholar
• ChinJMillerSCWadaMNaganoNNemethEFFoxJActivation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic ratsJ Am Soc Nephrol200011590391110770968
   PubMed Web of Science ®Google Scholar
• MizobuchiMHatamuraIOgataHSajiFUdaSShiizakiKCalcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiencyJ Am Soc Nephrol200415102579258715466262
   PubMed Web of Science ®Google Scholar
• de FranciscoALIzquierdoMCunninghamJPineraCPalomarRFresnedoGFCalcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcetNephrol Dial Transplant2008423
   Web of Science ®Google Scholar
• LomonteCVernaglioneLChimientiDBrunoACocolaSTeutonicoADoes vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?Clin J Am Soc Nephrol20083379479918322048
   PubMed Web of Science ®Google Scholar
• YamaguchiSYachikuSMorikawaMAnalysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidismJ Clin Endocrinol Metab199782826812689253354
   PubMed Web of Science ®Google Scholar
• MallucheHHMonier-FaugereMCWangGFrazaOJCharytanCCoburnJWAn assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidismClin Nephrol200869426927818397701
   PubMed Web of Science ®Google Scholar
• WangRXuCZhaoWZhangJCaoKYangBCalcium and polyamine regulated calcium-sensing receptors in cardiac tissuesEur J Biochem200327012268026812787035
   PubMedGoogle Scholar
• Tfelt-HansenJHansenJLSmajilovicSTerwilligerEFHaunsoSSheikhSPCalcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytesAm J Physiol Heart Circ Physiol20062903H1165117116243911
   PubMed Web of Science ®Google Scholar
• Farzaneh-FarAProudfootDWeissbergPLShanahanCMMatrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptorBiochem Biophys Res Commun2000277373674011062022
   PubMed Web of Science ®Google Scholar
• WangYBukoskiRDDistribution of the perivascular nerve Ca2+ receptor in rat arteriesBr J Pharmacol19981257139714049884066
   PubMed Web of Science ®Google Scholar
• WonnebergerKScofieldMAWangemannPEvidence for a calcium-sensing receptor in the vascular smooth muscle cells of the spiral modiolar arteryJ Membr Biol2000175320321210833530
   PubMed Web of Science ®Google Scholar
• SmajilovicSHansenJLChristoffersenTELewinESheikhSPTerwilligerEFExtracellular calcium sensing in rat aortic vascular smooth muscle cellsBiochem Biophys Res Commun200634841215122316919596
   PubMed Web of Science ®Google Scholar
• ZiegelsteinRCXiongYHeCHuQExpression of a functional extracellular calcium-sensing receptor in human aortic endothelial cellsBiochem Biophys Res Commun2006342115316316472767
   PubMed Web of Science ®Google Scholar
• SmajilovicSTfelt-HansenJCalcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular systemCardiovasc Res200775345746717466291
   PubMed Web of Science ®Google Scholar
• OgataHRitzEOdoniGAmannKOrthSRBeneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factorsJ Am Soc Nephrol200314495996712660330
   PubMed Web of Science ®Google Scholar
• CunninghamJDaneseMOlsonKKlassenPChertowGMEffects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidismKidney Int20056841793180016164656
   PubMed Web of Science ®Google Scholar
• MartinKJGonzalezEAGellensMHammLLAbboudHLindbergJ19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysisJ Am Soc Nephrol199898142714329697664
   PubMed Web of Science ®Google Scholar
• DelmezJAKelberJNorwoodKYGilesKSSlatopolskyEA controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patientsClin Nephrol200054430130811076106
   PubMed Web of Science ®Google Scholar
• CoyneDWGrieffMAhyaSNGilesKNorwoodKSlatopolskyEDifferential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patientsAm J Kidney Dis20024061283128812460048
   PubMed Web of Science ®Google Scholar
• JoistHEAhyaSNGilesKNorwoodKSlatopolskyECoyneDWDifferential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patientsClin Nephrol200665533534116724654
   PubMed Web of Science ®Google Scholar
• SpragueSMLlachFAmdahlMTaccettaCBatlleDParicalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney Int20036341483149012631365
   PubMed Web of Science ®Google Scholar
• BrandiLDaugaardHTvedegaardENielsenPKEgsmoseCStormTLong-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysisAm J Nephrol19921253113181488999
   PubMed Web of Science ®Google Scholar
• LindbergJMartinKJGonzalezEAAcchiardoSRValdinJRSoltanekCA long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal diseaseClin Nephrol200156431532311680662
   PubMed Web of Science ®Google Scholar
• AkizawaTSuzukiMAkibaTNishizawaYOhashiYOgataELong-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration studyNephrol Dial Transplant200217 Suppl 10283612386266
   PubMed Web of Science ®Google Scholar
• TengMWolfMLowrieEOfsthunNLazarusJMThadhaniRSurvival of patients undergoing hemodialysis with paricalcitol or calcitriol therapyN Engl J Med2003349544645612890843
   PubMed Web of Science ®Google Scholar
• TengMWolfMOfsthunMNLazarusJMHernanMACamargoCAJrActivated injectable vitamin D and hemodialysis survival: a historical cohort studyJ Am Soc Nephrol20051641115112515728786
   PubMed Web of Science ®Google Scholar
• Kalantar-ZadehKKuwaeNRegidorDLKovesdyCPKilpatrickRDShinabergerCSSurvival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney Int200670477178016820797
   PubMed Web of Science ®Google Scholar
• TentoriFHuntWCStidleyCARohrscheibMRBedrickEJMeyerKBMortality risk among hemodialysis patients receiving different vitamin D analogsKidney Int200670101858186517021609
   PubMed Web of Science ®Google Scholar
• Al-BadrWMartinKJVitamin D and Kidney DiseaseClin J Am Soc Nephrol200851
   PubMed Web of Science ®Google Scholar
• BrownAJSlatopolskyEDrug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney diseaseNat Clin Pract Endocrinol Metab200723213414417237840
   PubMedGoogle Scholar
• MehrotraRKermahDBudoffMSaluskyIBMaoSSGaoYLHypovitaminosis D in Chronic Kidney DiseaseClin J Am Soc Nephrol2008416
   Web of Science ®Google Scholar
• ZehnderDLandrayMJWheelerDCFraserWBlackwellLNuttallSCross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) studyNephron Clin Pract20071073c1091617890873
   PubMedGoogle Scholar
• SlatopolskyEBrownADussoARole of phosphorus in the pathogenesis of secondary hyperparathyroidismAm J Kidney Dis20011371 Suppl 2S54711158862
   PubMed Web of Science ®Google Scholar
• RowePSThe wrickkened pathways of FGF23, MEPE and PHEXCrit Rev Oral Biol Med200415526428115470265
   PubMedGoogle Scholar
• ZismanALHristovaMHoLTSpragueSMImpact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney diseaseAm J Nephrol2007271364317215573
   PubMed Web of Science ®Google Scholar
• Al-AlyZQaziRAGonzalezEAZeringueAMartinKJChanges in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKDAm J Kidney Dis2007501596817591525
   PubMed Web of Science ®Google Scholar
• ChandraPBinongoJNZieglerTRSchlangerLEWangWSomerenJTCholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot studyEndocr Pract2008141101718238736
   PubMedGoogle Scholar
• SaitoHKusanoKKinosakiMItoHHirataMSegawaHHuman fibroblast growth factor-23 mutants suppress Na+−dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 productionJ Biol Chem200327842206221112419819
   PubMed Web of Science ®Google Scholar
• LiuSTangWZhouJStubbsJRLuoQPiMFibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin DJ Am Soc Nephrol200651751305131516597685
   PubMed Web of Science ®Google Scholar
• KrajisnikTBjorklundPMarsellRLjunggrenOAkerstromGJonssonKBFibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cellsJ Endocrinol2007195112513117911404
   PubMed Web of Science ®Google Scholar
• ShimadaTHasegawaHYamazakiYMutoTHinoRTakeuchiYFGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasisJ Bone Miner Res200419342943515040831
   PubMed Web of Science ®Google Scholar
• PerwadFZhangMYTenenhouseHSPortaleAAFibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitroAm J Physiol Renal Physiol20072935F1577158317699549
   PubMed Web of Science ®Google Scholar
• LarssonTNisbethULjunggrenOJuppnerHJonssonKBCirculating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney Int20036462272227914633152
   PubMed Web of Science ®Google Scholar
• ShigematsuTKazamaJJYamashitaTFukumotoSHosoyaTGejyoFPossible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiencyAm J Kidney Dis200444225025615264182
   PubMed Web of Science ®Google Scholar
• GutierrezOIsakovaTRheeEShahAHolmesJColleroneGFibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney diseaseJ Am Soc Nephrol20051672205221515917335
   PubMed Web of Science ®Google Scholar
• CoburnJWMaungHMElangovanLGermainMJLindbergJSSpragueSMDoxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4Am J Kidney Dis200443587789015112179
   PubMed Web of Science ®Google Scholar
• GoodmanWGCalcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?Curr Opin Nephrol Hypertens200514435536015931004
   PubMed Web of Science ®Google Scholar
• KosCHKaraplisACPengJBHedigerMAGoltzmanDMohammadKSThe calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormoneJ Clin Invest200311171021102812671051
   PubMed Web of Science ®Google Scholar
• TuQPiMKarsentyGSimpsonLLiuSQuarlesLDRescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null backgroundJ Clin Invest2003111710293712671052
   PubMed Web of Science ®Google Scholar
• LiYCAmlingMPirroAEPriemelMMeuseJBaronRNormalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated miceEndocrinology199813910439143969751523
   PubMed Web of Science ®Google Scholar
• MartinLNKayathMJVieiraJGNose-AlbertiVParathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysisHistopathology199833146519726048
   PubMed Web of Science ®Google Scholar
• FukudaNTanakaHTominagaYFukagawaMKurokawaKSeinoYDecreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patientsJ Clin Invest1993923143614438397225
   PubMed Web of Science ®Google Scholar
• WangXSunBZhouFHuJYuXPengTVitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patientsChin Med J (Engl)2001114441041411780466
   PubMed Web of Science ®Google Scholar
• TokumotoMTsuruyaKFukudaKKanaiHKurokiSHirakataHReduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidismKidney Int20026241196120712234290
   PubMed Web of Science ®Google Scholar
• YanoSSugimotoTTsukamotoTChiharaKKobayashiAKitazawaSDecrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomasEur J Endocrinol2003148440341112656660
   PubMed Web of Science ®Google Scholar
• BrownAJZhongMFinchJRitterCMcCrackenRMorrisseyJRat calcium-sensing receptor is regulated by vitamin D but not by calciumAm J Physiol19962703 Pt 2F4544608780248
   PubMed Web of Science ®Google Scholar
• CanaffLHendyGNHuman calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin DJ Biol Chem200227733303373035012036954
   PubMed Web of Science ®Google Scholar
• TokumotoMTaniguchiMMatsuoDTsuruyaKHirakataHIidaMParathyroid cell growth in patients with advanced secondary hyper-parathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factorsTher Apher Dial20059Suppl 1S273416109139
   PubMed Web of Science ®Google Scholar
• LiuPTStengerSLiHWenzelLTanBHKrutzikSRToll-like receptor triggering of a vitamin D-mediated human antimicrobial responseScience200631157681770177316497887
   PubMed Web of Science ®Google Scholar
• PeterlikMCrossHSVitamin D and calcium deficits predispose for multiple chronic diseasesEur J Clin Invest200535529030415860041
   PubMed Web of Science ®Google Scholar
• GirasoleGWangJMPedrazzoniMPioliGBalottaCPasseriMAugmentation of monocyte chemotaxis by 1 alpha, 25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patientsJ Immunol19901458245924642212648
   PubMed Web of Science ®Google Scholar
• ProvvediniDMDeftosLJManolagasSC1,25-Dihydroxyvitamin D3 promotes in vitro morphologic and enzymatic changes in normal human monocytes consistent with their differentiation into macrophagesBone19867123283083846
   PubMed Web of Science ®Google Scholar
• OrikasaMKawaseTSuzukiAInduction of macrophagic and granulocytic differentiation of murine bone marrow progenitor cells by 1,25-dihydroxyvitamin D3Calcif Tissue Int19935331932008242472
   PubMed Web of Science ®Google Scholar
• Boltz-NitulescuGWillheimMSpittlerALeutmezerFTempferCWinklerSModulation of IgA, IgE, and IgG Fc receptor expression on human mononuclear phagocytes by 1 alpha,25-dihydroxyvitamin D3 and cytokinesJ Leukoc Biol19955822562627643018
   PubMed Web of Science ®Google Scholar
• CohenMSMeslerDESnipesRGGrayTK1,25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytesJ Immunol19861363104910533079794
   PubMed Web of Science ®Google Scholar
• SlyLMLopezMNauseefWMReinerNE1alpha, 25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidaseJ Biol Chem200127638354823549311461902
   PubMed Web of Science ®Google Scholar
• NnoahamKEClarkeALow serum vitamin D levels and tuberculosis: a systematic review and meta-analysisInt J Epidemiol200837111311918245055
   PubMed Web of Science ®Google Scholar
• GallieniMKamimuraSAhmedABravoEDelmezJSlatopolskyEKinetics of monocyte 1 alpha-hydroxylase in renal failureAm J Physiol19952684 Pt 2F7467537733332
   PubMed Web of Science ®Google Scholar
• PereiraMAJacobsDRJrVan HornLSlatteryMLKartashovAILudwigDSDairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA StudyJAMA2002287162081208911966382
   PubMed Web of Science ®Google Scholar
• FordESAjaniUAMcGuireLCLiuSConcentrations of serum vitamin D and the metabolic syndrome among US adultsDiabetes Care20052851228123015855599
   PubMed Web of Science ®Google Scholar
• LiuSSongYFordESMansonJEBuringJERidkerPMDietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US womenDiabetes Care200528122926293216306556
   PubMed Web of Science ®Google Scholar
• WuJGaramiMChengTGardnerDG1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytesJ Clin Invest1996977157715888601621
   PubMed Web of Science ®Google Scholar
• LiYCKongJWeiMChenZFLiuSQCaoLP1,25-Dihydroxyvi-tamin D(3) is a negative endocrine regulator of the renin-angiotensin systemJ Clin Invest2002110222923812122115
   PubMed Web of Science ®Google Scholar
• SpiegelDMRaggiPSmitsGBlockGAFactors associated with mortality in patients new to haemodialysisNephrol Dial Transplant200722123568357217617651
   PubMed Web of Science ®Google Scholar
• BlockGARaggiPBellasiAKooiengaLSpiegelDMMortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patientsKidney Int200771543844117200680
   PubMed Web of Science ®Google Scholar
• LopezIMendozaFJAguilera-TejeroEPerezJGuerreroFMartinDThe effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic ratsKidney Int200873330030718004298
   PubMed Web of Science ®Google Scholar